|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT01836757 |
|
Date of registration:
|
13/03/2013 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Cartilage
msm |
|
Scientific title:
|
The Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Joint Cartilage Associated With the Degeneration of the Chondrocyte |
|
Date of first enrolment:
|
September 2012 |
|
Target sample size:
|
100 |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT01836757 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care
|
|
Phase:
|
Phase 1
|
|
|
Countries of recruitment
|
|
Greece
| | | | | | | |
|
Contacts
|
|
Name:
|
Thomas Pagonis, MD, PhD |
|
Address:
|
|
|
Telephone:
|
00306980488686 |
|
Email:
|
iatros1@yahoo.com |
|
Affiliation:
|
|
|
|
Name:
|
Panagiotis Givisis, MD, PhD |
|
Address:
|
|
|
Telephone:
|
00306945264010 |
|
Email:
|
|
|
Affiliation:
|
|
|
|
Name:
|
Thomas Pagonis, MD, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Aristotle's University of Thessaloniki |
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Knee and hip OA
- men and women >45 years of age
Exclusion Criteria:
- any other type of arthritis
- chronic pain syndrome
- arthroscopic surgery in the past 8 months
- intra-articular corticosteroidsin the past 8 months
- hyaluronic acid injections in the past 8 months
- narcotic pain killers use
- renal or hepatic disease
- body mass index (BMI) >45 kg/m2
- cancer
Age minimum:
40 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Osteoarthritis
|
|
Intervention(s)
|
|
Drug: MethylSulfonylMethane (MSM)
|
|
Drug: Placebo
|
|
Primary Outcome(s)
|
|
Number of participants with improved Mobility
[Time Frame: 26 weeks]
|
|
Secondary Outcome(s)
|
|
Pain Scores on the Visual Analog Scale
[Time Frame: 26 weeks]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|